MX2018013882A - Seleccion directa de celulas que expresan niveles altos de proteinas heterodimericas usando vectores de complementacion intragenica de glutamina sintetasa. - Google Patents
Seleccion directa de celulas que expresan niveles altos de proteinas heterodimericas usando vectores de complementacion intragenica de glutamina sintetasa.Info
- Publication number
- MX2018013882A MX2018013882A MX2018013882A MX2018013882A MX2018013882A MX 2018013882 A MX2018013882 A MX 2018013882A MX 2018013882 A MX2018013882 A MX 2018013882A MX 2018013882 A MX2018013882 A MX 2018013882A MX 2018013882 A MX2018013882 A MX 2018013882A
- Authority
- MX
- Mexico
- Prior art keywords
- cells expressing
- high levels
- glutamine synthetase
- direct selection
- expressing high
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 2
- 102000005396 glutamine synthetase Human genes 0.000 title 1
- 108020002326 glutamine synthetase Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
- C12Y104/01—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with NAD+ or NADP+ as acceptor (1.4.1)
- C12Y104/01002—Glutamate dehydrogenase (1.4.1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
- C12Y603/04004—Adenylosuccinate synthase (6.3.4.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/04—Other carbon-nitrogen ligases (6.3.4)
- C12Y603/04005—Argininosuccinate synthase (6.3.4.5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
- C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Esta invención se refiere al campo general de la expresión recombinante de polipéptidos en cultivos celulares de animales. Más específicamente, la invención se refiere a la selección de células transfectadas con vectores modificados genéticamente de manera recombinante diseñados para expresar polipéptidos, en polipéptidos heterodiméricos particulares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662334966P | 2016-05-11 | 2016-05-11 | |
PCT/US2017/032139 WO2017197098A1 (en) | 2016-05-11 | 2017-05-11 | Direct selection of cells expressing high levels of heteromeric proteins using glutamine synthetase intragenic complementation vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018013882A true MX2018013882A (es) | 2019-03-14 |
Family
ID=58873869
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018013882A MX2018013882A (es) | 2016-05-11 | 2017-05-11 | Seleccion directa de celulas que expresan niveles altos de proteinas heterodimericas usando vectores de complementacion intragenica de glutamina sintetasa. |
MX2022009674A MX2022009674A (es) | 2016-05-11 | 2018-11-12 | Seleccion directa de celulas que expresan niveles altos de proteinas heterodimericas usando vectores de complementacion intragenica de glutamina sintetasa. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022009674A MX2022009674A (es) | 2016-05-11 | 2018-11-12 | Seleccion directa de celulas que expresan niveles altos de proteinas heterodimericas usando vectores de complementacion intragenica de glutamina sintetasa. |
Country Status (17)
Country | Link |
---|---|
US (2) | US11384140B2 (es) |
EP (2) | EP4067493A1 (es) |
JP (2) | JP6972022B2 (es) |
KR (2) | KR102439719B1 (es) |
CN (2) | CN115873904A (es) |
AU (2) | AU2017263454B2 (es) |
BR (1) | BR112018073316A2 (es) |
CA (1) | CA3024027A1 (es) |
CL (1) | CL2018003210A1 (es) |
EA (1) | EA201892588A1 (es) |
ES (1) | ES2914118T3 (es) |
IL (2) | IL300591A (es) |
MA (1) | MA44976A (es) |
MX (2) | MX2018013882A (es) |
SG (1) | SG11201810040WA (es) |
TW (2) | TWI821905B (es) |
WO (1) | WO2017197098A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110023500A (zh) * | 2016-11-16 | 2019-07-16 | 新加坡科技研究局 | 作为选择标记的减毒谷氨酰胺合成酶 |
CN111093641A (zh) | 2017-05-24 | 2020-05-01 | 托埃瑞斯有限责任公司 | 谷氨酰胺合成酶用于治疗高氨血症的用途 |
CN109988777A (zh) * | 2017-12-29 | 2019-07-09 | 南京金斯瑞生物科技有限公司 | 谷氨酰胺合成酶基因以及应用 |
US20220243222A1 (en) * | 2019-05-07 | 2022-08-04 | Amgen Inc. | Vectors and expression systems for producing recombinant proteins |
CN118103512A (zh) * | 2021-08-03 | 2024-05-28 | 上海臻格生物技术有限公司 | 用于真核表达系统的可选择标志物 |
WO2023180398A1 (en) | 2022-03-23 | 2023-09-28 | Boehringer Ingelheim International Gmbh | Bacterial glutamine synthetase as selection marker in mammalian cells |
WO2023180374A1 (en) | 2022-03-23 | 2023-09-28 | Boehringer Ingelheim International Gmbh | New glutamine synthetase variants as selection marker |
CN118006685B (zh) * | 2024-04-07 | 2024-07-23 | 上海碧博生物医药科技有限公司 | 一种快速的高表达单克隆细胞株构建方法 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
JPH0819508B2 (ja) | 1987-08-19 | 1996-02-28 | 三菱マテリアル株式会社 | Fe−Co基合金製高周波用磁芯材 |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5624818A (en) | 1991-09-09 | 1997-04-29 | Fred Hutchinson Cancer Research Center | Nucleic acids encoding regulatory proteins that dimerize with Mad or Max |
CA2121798C (en) | 1991-10-25 | 2007-07-24 | Richard J. Armitage | Novel cytokine |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5573925A (en) | 1994-11-28 | 1996-11-12 | The Wistar Institute Of Anatomy And Biology | P53 proteins with altered tetramerization domains |
ES2214541T3 (es) | 1995-06-07 | 2004-09-16 | Immunex Corporation | Muteina de cd40l. |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
JP2003504059A (ja) * | 1999-07-12 | 2003-02-04 | ジェネンテック・インコーポレーテッド | 発現ベクターと方法 |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
JP4266825B2 (ja) | 2001-09-20 | 2009-05-20 | イミユネツクス・コーポレイシヨン | ヘテロマーポリペプチドを発現する細胞の選択 |
GB0200977D0 (en) * | 2002-01-17 | 2002-03-06 | Lonza Biologics Plc | Glutamine-auxotrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium |
WO2004038003A2 (en) * | 2002-10-25 | 2004-05-06 | Five Prime Therapeutics, Inc. | Human polypeptides encoded by polynucleotides and methods of their use |
US7384744B2 (en) * | 2002-11-29 | 2008-06-10 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products |
US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
WO2005024015A1 (en) * | 2003-09-04 | 2005-03-17 | Medarex, Inc. | Expression vector |
EA011879B1 (ru) | 2004-09-24 | 2009-06-30 | Эмджин Инк. | МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ |
US8053238B2 (en) | 2005-10-31 | 2011-11-08 | Unhwa Corporation | Isolated population of plant single cells and method of preparing the same |
US20070254338A1 (en) * | 2006-04-24 | 2007-11-01 | Amgen Inc. | Method for making recombinant protein using complementation dependent DHFR mutants |
US20100221823A1 (en) | 2007-06-11 | 2010-09-02 | Amgen Inc. | Method for culturing mammalian cells to improve recombinant protein production |
WO2012027533A1 (en) | 2010-08-25 | 2012-03-01 | Gt Life Sciences, Inc. | Selectable markers and related methods |
WO2012063799A1 (ja) * | 2010-11-08 | 2012-05-18 | 日本ケミカルリサーチ株式会社 | 新規発現ベクター |
WO2012095514A1 (en) * | 2011-01-14 | 2012-07-19 | Vivalis | Recombinant protein production system |
US9133493B2 (en) | 2011-04-21 | 2015-09-15 | Amgen Inc. | Method for culturing mammalian cells to improve recombinant protein production |
AU2012203048A1 (en) * | 2011-05-24 | 2012-12-13 | Agency For Science, Technology And Research | IRES mediated multicistronic vectors |
KR101411740B1 (ko) * | 2012-05-29 | 2014-06-27 | 한화케미칼 주식회사 | 항체 발현용 바이시스트로닉 발현벡터 및 이를 이용한 항체의 생산 방법 |
-
2017
- 2017-05-11 KR KR1020217035841A patent/KR102439719B1/ko active IP Right Grant
- 2017-05-11 TW TW111105103A patent/TWI821905B/zh active
- 2017-05-11 CN CN202211654230.0A patent/CN115873904A/zh active Pending
- 2017-05-11 WO PCT/US2017/032139 patent/WO2017197098A1/en active Application Filing
- 2017-05-11 EA EA201892588A patent/EA201892588A1/ru unknown
- 2017-05-11 MA MA044976A patent/MA44976A/fr unknown
- 2017-05-11 EP EP22159835.2A patent/EP4067493A1/en active Pending
- 2017-05-11 CA CA3024027A patent/CA3024027A1/en active Pending
- 2017-05-11 KR KR1020187035185A patent/KR102323519B1/ko active IP Right Grant
- 2017-05-11 IL IL300591A patent/IL300591A/en unknown
- 2017-05-11 AU AU2017263454A patent/AU2017263454B2/en active Active
- 2017-05-11 SG SG11201810040WA patent/SG11201810040WA/en unknown
- 2017-05-11 CN CN201780034550.7A patent/CN109219660B/zh active Active
- 2017-05-11 MX MX2018013882A patent/MX2018013882A/es unknown
- 2017-05-11 JP JP2018559814A patent/JP6972022B2/ja active Active
- 2017-05-11 TW TW106115604A patent/TWI757291B/zh active
- 2017-05-11 US US16/099,986 patent/US11384140B2/en active Active
- 2017-05-11 BR BR112018073316A patent/BR112018073316A2/pt not_active Application Discontinuation
- 2017-05-11 EP EP17727027.9A patent/EP3455359B1/en active Active
- 2017-05-11 ES ES17727027T patent/ES2914118T3/es active Active
-
2018
- 2018-11-11 IL IL262923A patent/IL262923B2/en unknown
- 2018-11-12 CL CL2018003210A patent/CL2018003210A1/es unknown
- 2018-11-12 MX MX2022009674A patent/MX2022009674A/es unknown
-
2021
- 2021-11-01 JP JP2021178542A patent/JP7344949B2/ja active Active
-
2022
- 2022-05-26 US US17/825,793 patent/US20230048658A1/en active Pending
-
2023
- 2023-02-08 AU AU2023200660A patent/AU2023200660A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022009674A (es) | Seleccion directa de celulas que expresan niveles altos de proteinas heterodimericas usando vectores de complementacion intragenica de glutamina sintetasa. | |
PH12018502645A1 (en) | Optimized mini-dystrophin genes and expression cassettes and their use | |
MX2021008142A (es) | Metodos para cosechar cultivos de celulas de mamifero. | |
PH12018502361A1 (en) | Gdf15 fusion proteins and uses thereof | |
CL2019003842A1 (es) | Vectores virales recombinantes con tropismo modificado y usos de estos para la introducción dirigida de material genético a células humanas. | |
EA201992001A1 (ru) | Композиции и способы повышения экспрессии генов | |
MX2019002903A (es) | Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos. | |
EA202090931A3 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
EA201891137A1 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a | |
MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
MX2016003944A (es) | Composiciones y formulaciones para mantener y aumentar la masa muscular, fuerza y rendimiento y metodos de produccion y usos de los mismos. | |
MX2017007127A (es) | Composiciones que comprenden polipeptidos que tienen actividad xilanasa y polipeptidos que tienen actividad arabinofuranosidasa. | |
AU2016335217A8 (en) | Antigen receptors and uses thereof | |
MX2020001791A (es) | Modificacion de celulas t. | |
EA201691691A1 (ru) | Белки слияния tatk-cdkl5, их композиции, составы и применение | |
EA201791918A1 (ru) | Модификация белков клеток-хозяев | |
AU2015279552A8 (en) | Neural cells expressing adenovirus E4ORF1, and methods of making and using the same | |
EA201891138A1 (ru) | Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a | |
MX2018013875A (es) | Composiciones que comprenden polipeptidos que tienen actividad galactanasa y polipeptidos que tienen actividad beta-galactosidasa. | |
MX2020002903A (es) | Método para potenciar la expresión de arn en una célula. | |
MX2015012281A (es) | Proteinas de union a tnf mejoradas. | |
MY193535A (en) | Cell culture methods | |
MX2018014434A (es) | Composiciones que comprenden polipeptidos que tienen actividad galactanasa y polipeptidos que tienen actividad beta-galactosidasa. | |
MX2019010941A (es) | Receptores de antigeno y usos de los mismos. |